Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengqing Fengtongning is a traditional Chinese medicine (TCM) preparation whose primary active ingredient is sinomenine hydrochloride. It is available in both tablet and injection forms. Sinomenine is an alkaloid extracted from the plant Sinomenium acutum and exhibits immunosuppressive and anti-inflammatory properties. The drug has been widely used in China for the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis (RA), lumbar disc herniation, cervical spondylosis, osteoarthritis, chronic nephritis, rheumatism, and gout. Mechanistically, it acts by modulating immune responses and reducing inflammation through multiple targets relevant to these conditions[1][2][5][6]. Clinical studies have shown that when combined with methotrexate for RA or with urate-lowering therapy for gout prophylaxis, it can improve clinical outcomes compared to monotherapy[2][5][6]. Adverse effects are generally mild but may include skin reactions such as flushing or rash[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhengqing fengtongning.